KLP Kapitalforvaltning AS Invests $10.28 Million in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

KLP Kapitalforvaltning AS bought a new stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 43,700 shares of the biopharmaceutical company's stock, valued at approximately $10,283,000.

Several other institutional investors have also recently made changes to their positions in the stock. Regeneron Pharmaceuticals Inc. bought a new stake in shares of Alnylam Pharmaceuticals during the 4th quarter valued at $1,045,822,000. Geode Capital Management LLC increased its holdings in Alnylam Pharmaceuticals by 3.2% during the 3rd quarter. Geode Capital Management LLC now owns 2,147,203 shares of the biopharmaceutical company's stock worth $589,209,000 after acquiring an additional 66,928 shares during the period. American Century Companies Inc. raised its position in shares of Alnylam Pharmaceuticals by 0.7% in the fourth quarter. American Century Companies Inc. now owns 1,604,024 shares of the biopharmaceutical company's stock worth $377,443,000 after buying an additional 11,291 shares in the last quarter. Charles Schwab Investment Management Inc. grew its position in Alnylam Pharmaceuticals by 5.5% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 513,962 shares of the biopharmaceutical company's stock worth $120,940,000 after buying an additional 26,614 shares in the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. increased its stake in Alnylam Pharmaceuticals by 3.0% in the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 286,703 shares of the biopharmaceutical company's stock worth $67,464,000 after acquiring an additional 8,462 shares during the last quarter. Hedge funds and other institutional investors own 92.97% of the company's stock.

Remove Ads

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the stock. Morgan Stanley raised their target price on shares of Alnylam Pharmaceuticals from $275.00 to $284.00 and gave the company an "equal weight" rating in a research note on Friday, February 14th. StockNews.com downgraded shares of Alnylam Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Friday, March 21st. Chardan Capital reissued a "buy" rating and set a $300.00 price target on shares of Alnylam Pharmaceuticals in a research note on Friday, March 21st. Canaccord Genuity Group upped their price objective on shares of Alnylam Pharmaceuticals from $385.00 to $390.00 and gave the company a "buy" rating in a research note on Friday, March 21st. Finally, Bank of America lifted their target price on shares of Alnylam Pharmaceuticals from $302.00 to $325.00 and gave the stock a "buy" rating in a research report on Friday, March 21st. One investment analyst has rated the stock with a sell rating, five have given a hold rating and twenty have given a buy rating to the stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $312.30.

Alnylam Pharmaceuticals Stock Down 0.9 %

Shares of NASDAQ:ALNY traded down $2.56 during trading on Friday, hitting $268.46. The stock had a trading volume of 683,886 shares, compared to its average volume of 830,396. The company has a quick ratio of 2.71, a current ratio of 2.78 and a debt-to-equity ratio of 15.27. Alnylam Pharmaceuticals, Inc. has a 12 month low of $141.98 and a 12 month high of $304.39. The company has a market capitalization of $34.92 billion, a PE ratio of -123.71 and a beta of 0.39. The firm's fifty day moving average is $259.86 and its 200 day moving average is $260.50.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last announced its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.62) by ($0.03). Analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Insiders Place Their Bets

In other Alnylam Pharmaceuticals news, EVP Kevin Joseph Fitzgerald sold 663 shares of the business's stock in a transaction on Friday, February 14th. The stock was sold at an average price of $255.21, for a total value of $169,204.23. Following the sale, the executive vice president now directly owns 14,321 shares of the company's stock, valued at approximately $3,654,862.41. The trade was a 4.42 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Phillip A. Sharp sold 11,250 shares of the firm's stock in a transaction on Thursday, January 23rd. The shares were sold at an average price of $275.00, for a total value of $3,093,750.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 71,234 shares of company stock worth $19,958,097. 1.50% of the stock is currently owned by company insiders.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.